ArticleCureus2025
Comparative Assessment of Transcutaneous Bilirubin Versus Total Serum Bilirubin Measurements in Preterm Infants.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperbilirubinemia is a common condition, particularly among preterm neonates. Although transcutaneous bilirubin (TCB) measurement offers a non-invasive modality for bilirubin assessment, its diagnostic accuracy in preterm populations remains incompletely characterized. This study addresses a knowledge gap by focusing on preterm neonates between 28 and 35 weeks of gestation and evaluating the concordance between TCB and total serum bilirubin (TsB) measurements. MATERIALS AND
methodsA prospective cohort study was conducted at a tertiary care academic medical center between April 2023 and February 2024. The cohort included preterm neonates (≤35 weeks of gestation) admitted to the Neonatal Intensive Care Unit (NICU). TCB measurements were obtained within two hours of each TSB sampling using BiliCare™, a transcutaneous bilirubin meter. Statistical analyses, including Bland-Altman plots and Lin's concordance correlation coefficient (CCC), were used to evaluate the agreement between the two methods, TCB and TsB.
resultsA total of 300 paired bilirubin measurements from preterm neonates (gestational age range: 24-35 weeks) were analyzed. TCB and TsB demonstrated substantial concordance, with CCC values of 0.88 for neonates born at ≤28 weeks, 0.92 for those born at 29-32 weeks, and 0.95 for those born at>32 weeks. Minor variability and systematic bias were noted. The limits of agreement across all groups fell within a clinically acceptable range of ±4 mg/dL.
conclusionTCB represents a viable non-invasive alternative to TsB for bilirubin monitoring in preterm neonates with hyperbilirubinemia, potentially minimizing the need for frequent invasive blood sampling. However, the observed variability across gestational age subgroups underlines the need for cautious interpretation, particularly in subpopulations where discrepancies may occur. Further investigations are warranted to optimize the application of TCB in larger neonatal cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.